Value of bevacizumab in treatment of colorectal cancer: A meta-analysis

Table 1 Baseline characteristics of the included studies

Ref.	No. of cases (control group/treatment group)	Bevacizumab treatment regimen	Modified Jadad score
Kabbinavar et al[9]	104 (36/68)	5 mg/kg or 10 mg/kg every 14 d	4
Kabbinavar et al[10]	209 (105/104)	5 mg/kg every 14 d	5
Tebbutt et al[11]	312 (156/156)	7.5 mg/kg every 21 d	4
Stathopoulos et al[6]	224 (108/114)	7.5 mg/kg every 21 d	4
Saltz et al[7]	1400 (701/699)	5 mg/kg every 14 dor 7.5 mg/kg every 21 d	6
Hurwitz et al[12]	813 (411/402)	5 mg/kg every 21 d	4
Giantonio et al[8]	577 (291/286)	10 mg/kg every 14 d	3
Guan et al[13]	214 (72/142)	5 mg/kg every 14 d	4
de Gramont et al[14]	2306 (1151/1155)	5 mg/kg every 14 d	4
Bennouna et al[15]	820 (411/409)	5 mg/kg every 14 d or 7.5 mg/kg every 14 d	5